H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target ...
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...
After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
The FDA met resistance from a three-judge panel Wednesday over its decision to refuse approval of Vanda Pharmaceuticals Inc.’s jet lag disorder drug. At issue in arguments before the US Court of ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The US Supreme Court declined Monday to take up a challenge from Vanda Pharmaceuticals Inc. over what constitutes a “line extension” drug under the federal government’s Medicaid Drug Rebate Program.
Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The firm has a market capitalization of $268.22 million, a P/E ratio of -16.43 and a beta of 0.77. Insider Buying and ...